

Levosimendan PharmIdea

2.5mg/ml concentrate for solution for infusion 5 ml vials

New management of acute heart failure

**An inotrope agent with a unique mode of action –
cardioprotection, inotropy and vasodilation**

Levosimendan is the only inodilator (calcium sensitizer and potassium channel opener) to provide long lasting hemodynamic benefits and symptom control to patients with acute heart failure and in need of inotropic therapy

INDICATIONS

Levosimendan is indicated for the shortterm treatment of acutely decompensated severe chronic heart failure (ADHF) in situations where conventional therapy is not sufficient and in cases where inotropic support is considered appropriate

ADVANTAGES

- Levosimendan increases myocardial contractility without increasing myocardial oxygen demand
- Long lasting hemodynamic stabilization
- Synergies with β -blockers
- Shorter hospital stay
- Reduced re-hospitalization

ADMINISTRATION

I/v infusion loading dose 6 to 12 $\mu\text{g}/\text{kg}$ over 10 minutes followed by 0.05 to 0.2 $\mu\text{g}/\text{kg}/\text{min}$ as a continuous infusion

Pharmacotherapeutic group: Other cardiac stimulants (calcium sensitizer)

ATC code: C01CX08

Storage condition: Store at 2 – 8 °C.

Manufacturer: PharmIdea SIA, 4 Rupnicu Str., Olaine, LV 2114, Latvia

pharmidea@pharmidea.lv